RT Journal Article
SR Electronic
T1 DPI-3290 [(+)-3-((α-<em>R</em>)-α-((2<em>S</em>,5<em>R</em>)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-<em>N</em>-(3-fluorophenyl)-<em>N</em>-methylbenzamide]. II. A Mixed Opioid Agonist with Potent Antinociceptive Activity and Limited Effects on Respiratory Function
JF Journal of Pharmacology and Experimental Therapeutics
JO J Pharmacol Exp Ther
FD American Society for Pharmacology and Experimental Therapeutics
SP 1227
OP 1233
DO 10.1124/jpet.103.054429
VO 307
IS 3
A1 Peter J. Gengo
A1 Hugh O. Pettit
A1 Scott J. O'Neill
A1 Ying Fu Su
A1 Robert McNutt
A1 Kwen-Jen Chang
YR 2003
UL http://jpet.aspetjournals.org/content/307/3/1227.abstract
AB Allyl-2,5-dimethyl-1-piperazines have been of interest as analgesic agents for the management of moderate-to-severe pain. In this study, we compared the antinociceptive properties and respiratory depressant activity of one such agent, (+)-3-((α-R)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide (DPI-3290), with those of established narcotic analgesics, morphine and fentanyl. Intravenous administration of DPI-3290 in conscious laboratory rats increased antinociception in a dose-dependent manner with a corresponding ED50 value of 0.05 ± 0.0072 mg/kg. Simultaneous measurement of arterial blood gas in animals treated with DPI-3290 demonstrated dose-dependent increases in pCO2 with an ED50 value of 0.91 ± 0.22 mg/kg. In comparison, morphine and fentanyl increased antinociception in rats with ED50 values of 2.01 ± 0.0005 and 0.0034 ± 0.00024 mg/kg, respectively, and the ED50 value for morphine-induced changes in pCO2 was 4.23 ± 0.72 mg/kg, whereas the ED50 value for fentanyl-induced changes in pCO2 was 0.0127 ± 0.0035 mg/kg. A separate series of experiments were designed to examine the effects of DPI-3290 on μ-opioid receptor induced antinociception and hypercapnia. Intravenous bolus doses of DPI-3290 that ranged from 0.2 to 1.0 mg/kg had no effect on antinociception mediated by alfentanil (2 μg/kg/min i.v.) but reduced hypercapnia by approximately 50%. Results from these studies demonstrate the equivalent antinociceptive efficacy of DPI-3290, morphine, and fentanyl but dramatic differences in the hypercapnia that antinociceptive doses of these drugs produce. When measured simultaneously, DPI-3290 had an 18.2-fold difference in the ratio comparing the ED50 value for antinociception with the ED50 value for changes in pCO2; this ratio was 2.1 for morphine and 3.7 for fentanyl. Furthermore, DPI-3290 reduced the alfentanil-mediated hypercapnia without any effect on antinociception. Together, the balanced opioid agonist activity of DPI-3290 may provide a means of powerful analgesia while mitigating the μ-opioid receptor-mediated hypercapnia. The American Society for Pharmacology and Experimental Therapeutics